20 reports

AND GOODERHAM, M. (2017) ' PSORIASIS, DEPRESSION, AND SUICIDALITY. ', SKIN THERAPY LETTER, ##(##), PP. ##-##.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Novartis AG
  • Pfizer Inc.

OTHER SIDE EFFECTS OF REMICADE INCLUDE NAUSEA, ABDOMINAL PAIN, WORSENING HEART FAILURE, HYPERSENSITIVITY REACTIONS, FEVER, HEADACHE, DEPRESSION, AND ##. ##. ## SAFETY the formation of anti-TNF-α antibodies (Rutgeerts et al., 2005).

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • AbbVie Inc.
  • Pfizer Inc.

These severe AEs included confusion and shortness of breath, altered mental status and depression, and hypomagnesemia.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Novartis AG
  • Pfizer Inc.

" Cost to patients is the number one issue [unmet need], number one. "

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • AbbVie Inc.
  • Pfizer Inc.

GENOME MEDICINE; ##(##): ##.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Pfizer Inc.
  • Remicade group

Alzheimer's disease

4385 5000 3900

Depression is a common co-morbidity in Alzheimer' s disease, with prevalence rates of ##-##%.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Eli Lilly & Co.
  • Roche Group

THE OTEZLA PACKAGE INSERT REPORTS AN INCREASE IN ADVERSE REACTIONS, INCLUDING DEPRESSION AND WEIGHT LOSS.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Remicade group
  • Roche Group

Multiple sclerosis

4385 5000 3900

print=##& prin t=## [Accessed ## March 2013].

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Actelion Ltd
  • Biogen Idec Inc.

Rheumatoid arthritis

4385 5000 3900

Another very common co-morbidity in the US and five major EU markets is depression.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Pfizer Inc.
  • Roche Group
  • OMALIZUMAB - DRUG PROFILE

Negative effects of CIU / CSU on quality of life may include sleep deprivation and psychological co morbidities such as depression and anxiety.

  • Allergy
  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Product Initiative
  • OMALIZUMAB - DRUG PROFILE

Negative effects of CIU / CSU on quality of life may include sleep deprivation and psychological comorbidities such as depression and anxiety.

  • Allergy
  • Immunotherapy
  • Therapy
  • Japan
  • Product Initiative

THIS IS UTILIZED TO TREAT NEUROLOGICAL DISORDERS LIKE EPILEPSY AND DEPRESSION.

  • Immunotherapy
  • Injectable Delivery
  • Mental Health
  • Japan
  • Medtronic, Inc.

Article ##.

  • Immunotherapy
  • Injectable Delivery
  • Pharmaceutical
  • Therapy
  • Japan

The Lancet, ##(##), ##-## < DOI> ##. ##/ S##-##(##)##- ##< / DOI>.

  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited

ONE UNIT REFERS TO ONE CDU.

  • Injectable Delivery
  • Peripheral Vascular Device
  • Japan
  • Market Size
  • Boston Scientific Corporation

The prominent features of this report are - ##.

  • Clinical Trial
  • Immunotherapy
  • Injectable Delivery
  • Pharmaceutical
  • Japan

RMD Open, ##(Suppl ##), e## < DOI> ##. ##/ rmdopen-2015- ##< / DOI>.

  • Immunotherapy
  • Japan
  • Celgene Corporation
  • Johnson & Johnson
  • Novartis AG

The prominent features of this report are - ##.

  • Clinical Trial
  • Immunotherapy
  • Injectable Delivery
  • Pharmaceutical
  • Japan

Motiva (nefiracetam, DM ## and DZL ##) was under development for the treatment of apathy (post-stroke, Parkinson' s, brain injury), depression, dementia associated with Alzheimer' s disease or secondary to cerebrovascular disorders.

  • Cancer
  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Daiichi Sankyo Company

Psoriasis

4385 5000 3900

BIBLIOGRAPHY Psoriasis Disease Coverage | Forecast: Psoriasis DMKC## US ## ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## ## ## Spain ## ## ## ## ## ## ## ## ## ## UK ## ## ## ## ##

  • Autoimmune Disease
  • Immunotherapy
  • Injectable Delivery
  • Japan
  • Amgen Inc.